Cargando…

Constitutive Function of the Ikaros Transcription Factor in Primary Leukemia Cells from Pediatric Newly Diagnosed High-Risk and Relapsed B-precursor ALL Patients

We examined the constitutive function of the Ikaros (IK) transcription factor in blast cells from pediatric B-precursor acute lymphoblastic leukemia (BPL) patients using multiple assay platforms and bioinformatics tools. We found no evidence of diminished IK expression or function for primary cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uckun, Fatih M., Ma, Hong, Ishkhanian, Rita, Arellano, Martha, Shahidzadeh, Anoush, Termuhlen, Amanda, Gaynon, Paul S., Qazi, Sanjive
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835424/ https://www.ncbi.nlm.nih.gov/pubmed/24278314 http://dx.doi.org/10.1371/journal.pone.0080732

Ejemplares similares

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Uckun, Fatih M., et al.
Publicado: (2014)

CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL
por: Qazi, Sanjive, et al.
Publicado: (2023)

Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma
por: Uckun, Fatih M., et al.
Publicado: (2018)

Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas
por: Uckun, Fatih M., et al.
Publicado: (2018)

ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma
por: Uckun, Fatih M., et al.
Publicado: (2022)

Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance
por: Uckun, Fatih M., et al.
Publicado: (2022)

Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome
por: Qazi, Sanjive, et al.
Publicado: (2023)

Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes
por: Uckun, Fatih M., et al.
Publicado: (2023)

Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice()
por: Uckun, Fatih M., et al.
Publicado: (2015)

Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand × Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-resistant B-precursor Acute Lymphoblastic Leukemia in Mice()
por: Uckun, Fatih M., et al.
Publicado: (2015)

High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma
por: Uckun, Fatih M., et al.
Publicado: (2023)

Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up
por: Uckun, Fatih M., et al.
Publicado: (2019)

A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies
por: Uckun, Fatih M., et al.
Publicado: (2014)

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
por: Uckun, Fatih M., et al.
Publicado: (2021)

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia
por: Uckun, Fatih M., et al.
Publicado: (2019)

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
por: Watts, Justin, et al.
Publicado: (2022)

A Previously Unknown Unique Challenge for Inhibitors of SYK ATP-Binding Site: Role of SYK as A Cell Cycle Checkpoint Regulator()
por: Uckun, Fatih M., et al.
Publicado: (2014)

Development of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL
por: Uckun, Fatih M., et al.
Publicado: (2015)

The Ikaros family of zinc-finger proteins
por: Fan, Yingzhi, et al.
Publicado: (2016)

A Functional Polymorphism in the CEBPE Gene Promoter Influences Acute Lymphoblastic Leukemia Risk through Interaction with the Hematopoietic Transcription Factor Ikaros
por: Wiemels, Joseph L., et al.
Publicado: (2015)

Sumoylation Inhibits the Growth Suppressive Properties of Ikaros
por: Apostolov, Apostol, et al.
Publicado: (2016)

Realizing the Potential for Recipient Immune Cells in Adoptive Immune Therapy
por: Qazi, Sanjive
Publicado: (2016)

Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1(+) pre–B ALL
por: Schjerven, Hilde, et al.
Publicado: (2017)

An Ikaros Promoter Element with Dual Epigenetic and Transcriptional Activities
por: Perotti, Elizabeth A., et al.
Publicado: (2015)

Correction: Sumoylation Inhibits the Growth Suppressive Properties of Ikaros
Publicado: (2016)

Ikaros Proteins in Tumor: Current Perspectives and New Developments
por: Xia, Ruolan, et al.
Publicado: (2021)

Ikaros deficiency is associated with aggressive BCR-ABL1 B-cell precursor acute lymphoblastic leukemia independent of the lineage and developmental origin
por: Simand, Célestine, et al.
Publicado: (2021)

Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2022)

Defects in Hemopoietic Stem Cell Activity in Ikaros Mutant Mice
por: Nichogiannopoulou, Aliki, et al.
Publicado: (1999)

Differential regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros
por: Schjerven, Hilde, et al.
Publicado: (2013)

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma
por: Krönke, Jan, et al.
Publicado: (2017)

Ikaros-Associated Diseases: From Mice to Humans and Back Again
por: Boast, Brigette, et al.
Publicado: (2021)

Ikaros Regulates microRNA Networks in Acute Lymphoblastic Leukemia
por: Kogut, Sophie, et al.
Publicado: (2022)

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2021)

Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients
por: Yue, Xiaoyan, et al.
Publicado: (2022)

Ikaros controls isotype selection during immunoglobulin class switch recombination
por: Sellars, MacLean, et al.
Publicado: (2009)

Murine Pancreatic Adenocarcinoma Reduces Ikaros Expression and Disrupts T Cell Homeostasis
por: Nelson, Nadine, et al.
Publicado: (2015)

The Role of the Ikaros Family of Transcription Factors in Regulatory T cell Development and Function
por: Seng, Amara, et al.
Publicado: (2017)

Ikaros antagonizes DNA binding by STAT5 in pre-B cells
por: Heizmann, Beate, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vcu37ml49dm1qmesni0eatjn2v